In this episode, an expert panel reviews a prostate cancer patient’s journey from diagnosis through treatment and survivorship, including treatment decision-making and post-treatment management considerations.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

In this episode, an expert panel reviews a bladder cancer patient journey, including symptom recognition, diagnostic evaluation, treatment decision-making, systemic therapy, and survivorship considerations.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

Dr. Herbert Lepor reviews his institution's long-term experience with focal therapy for prostate cancer.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

Sima P. Porten, MD, MPH, FACS, Associate Professor of Urology, University of California, San Francisco, San Francisco, California, presents a complex bladder preservation case to a group of experts, and highlights the rising circulating tumor DNA in the absence of radiographic or pathologic recurrence, prompting debate regarding surveillance versus systemic therapy. 

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

This talk was presented at the ⁠⁠⁠⁠⁠⁠⁠⁠⁠International Bladder Cancer Update 2025 Expert Forum⁠ held from December 5-7, 2025.

Evan Y. Yu, MD, Professor of Oncology, University of Washington, Seattle, Washington, reviews novel targeted treatment strategies for prostate cancer beyond androgen receptor and PSMA-directed therapies.

This talk was presented at the ⁠Southwest Prostate Cancer Symposium 2025 held from October 23-25, 2025.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

Dr. Rahul Mehan discusses integrating diagnosis, treatment, and multidisciplinary care into a urology-led one-stop clinic for prostate cancer management.

This talk was presented at the 12th Urology Today conference held from October 31-November 2, 2025.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

⁠Steven E. Finkelstein, MD, DABR, FACRO⁠, and ⁠Patrick Soon-Shiong, MD⁠, delve into the interplay between radiation therapy and immunotherapy in prostate cancer care.

This talk was presented at the ⁠9th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer⁠, from September 15-17, 2025.

Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠⁠

Leonard G. Gomella, MD, FACS, and Brian T. Helfand, MD, PhD, discuss genetic testing in prostate cancer risk assessment and management.

This panel was presented at the ⁠35th Annual International Prostate Cancer Update⁠ from February 9-12, 2025 in Vail, Colorado.

Website: ⁠⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠

A panel discusses intermittent versus continuous androgen deprivation therapy (ADT) and its impact on prostate cancer outcomes.

Contributors include:

• David M. Albala, MD, Chief of Urology at Crouse Hospital in Syracuse, New York.
• Andrew W. Hahn, MD, Assistant Professor of Genitourinary Medical Oncology at the MD Anderson Cancer Center in Houston, Texas.

• Brian T. Helfand, MD, PhD, Chief of the Division of Urology, NorthShore University HealthSystem, Evanston, Illinois.

• Ronald P. Kaufman, Jr., MD, Associate Professor of Surgery in the department of Urology, Albany Medical College, Albany, New York.
• Christian P. Pavlovich, MD, Director of the Prostate Cancer Active Surveillance Program, Johns Hopkins, Baltimore, Maryland.
• A. Oliver Sartor, MD, Director of the Transformational Prostate Cancer Research Center, Metairie, Louisiana.

This panel was presented at the 35th Annual International Prostate Cancer Update from February 9-12, 2025 in Vail, Colorado.

Website: ⁠⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠⁠x.com/GRUrology⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠⁠

A panel of experts discuss advancements in managing benign prostatic hyperplasia, focusing on minimally invasive surgical therapies.Contributors include:

• Mitchell R. Humphreys, MD, Professor and Chair of Urology, Mayo Clinic, Phoenix, Arizona.
• Sunchin Kim, MD, Assistant Professor of Urology, University of Arizona College of Medicine in Tucson, Arizona.
• Faysal A. Yafi, MD, FRCSC, Associate Professor and Vice-Chair of Urology, University of California Irvine, Orange, California.

This panel discussion was given at the ⁠31th Annual Perspectives in Urology: Point Counterpoint

Find us:

Website: ⁠⁠⁠⁠⁠grandroundsinurology.com⁠⁠⁠⁠⁠

Twitter/X: ⁠⁠⁠x.com/GRUrology⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠linkedin.com/company/grand-rounds-in-urology/⁠⁠⁠⁠⁠